K. Schumacher

发表

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

J. Baselga, H. Rugo, D. Juric, 2019, JAMA oncology.

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

P. Paik, S. Matsumoto, Hiroshi Tanaka, 2021, Japanese journal of clinical oncology.

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Catherine Jorand Lebrun, C. Stroh, R. Rosell, 2020, iScience.

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.

C. Dooms, Yi-long Wu, J. Mazières, 2021, Future oncology.

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).

P. Paik, J. V. van Meerbeeck, L. Paz-Ares, 2021 .

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

E. Smit, J. Heymach, Keunchil Park, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

K. O'Byrne, Keunchil Park, F. de Marinis, 2012, The Lancet. Oncology.

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

K. O'Byrne, F. de Marinis, J. von Pawel, 2011, The Lancet. Oncology.

Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.

R. Schlegel, M. Peters, M. Pinzon-Ortiz, 2013 .

Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.

E. Smit, P. Paik, J. Mazières, 2021 .

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.

R. Sullivan, K. Flaherty, Simon Wandel, 2013 .

INNV-21. COMPLETE RESPONSE TO ADJUVANT TEPOTINIB IN A PATIENT WITH NEWLY DIAGNOSED DISSEMINATED GLIOBLASTOMA (GBM) HARBORING MET AMPLIFICATION

J. Degroot, Alexander Ou, B. O'Brien, 2021, Neuro-Oncology.

Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion.

K. Highsmith, K. Schumacher, A. Aaroe, 2024, The oncologist.